Newsroom

  • Category

  • By Date

  • Press Release

    07 April 26

    Aurobindo arm CuraTeQ reports positive Phase 3 results for allergy drug BP11

    Aurobindo Pharma unit CuraTeQ reports positive Phase 3 data for Xolair biosimilar BP11 in chronic spontaneous urticaria, plans EMA and FDA filings by end of Q2 2026

    Read more
  • Press Release

    12 February 26

    Aurobindo Pharma Targets 2029 as Turning Point for Its Biosimilars Business

    Aurobindo Pharma expects its biosimilars division to become a major growth driver, targeting 2029 as a key turning point with expansion across Europe, the US, and emerging global markets.

    Read more
  • Press Release

    19 September 25

    CuraTeQ Biologics announces positive Phase 3 study results for Denosumab biosimilar

    Read more